Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Pipeline Review, H2 2017

Published: Aug, 2017 | Pages: 113 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Pipeline Review, H2 2017

Summary

Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The latest report Receptor Tyrosine Protein Kinase ERBB 4 - Pipeline Review, H2 2017, outlays comprehensive information on the Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Receptor tyrosine-protein kinase erbB-4 is an enzyme that in humans is encoded by the ERBB4 gene. Receptor tyrosine-protein kinase erbB-4 is a receptor tyrosine kinase that is a member of the epidermal growth factor receptor subfamily. it plays an essential role as cell surface receptor for neuregulins and EGF family members and regulates development of the heart, the central nervous system and the mammary gland, gene transcription, cell proliferation, differentiation, migration and apoptosis. It is required for normal cardiac muscle differentiation during embryonic development, and for postnatal cardiomyocyte proliferation, normal development of the embryonic central nervous system, especially for normal neural crest cell migration, normal axon guidance, mammary gland differentiation, induction of milk proteins and lactation. It acts as cell-surface receptor for the neuregulins NRG1, NRG2, NRG3 and NRG4 and the EGF family members BTC, EREG and HBEGF. Ligand binding triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors.  The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 4, 1, 4, 2 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System and Gastrointestinal which include indications Gastric Cancer, Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Colorectal Cancer, Esophageal Cancer, Solid Tumor, Breast Cancer, Glioblastoma Multiforme (GBM), Bile Duct Cancer (Cholangiocarcinoma), Low-Grade Glioma, Lung Adenocarcinoma, Metastatic Brain Tumor, Pancreatic Cancer, Recurrent Glioblastoma Multiforme (GBM), Squamous Cell Carcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Biliary Tumor, Brain Cancer, Cervical Cancer, Chordoma, Chronic Heart Failure, Crohn's Disease (Regional Enteritis), Endometrial Cancer, Ependymoma, Gallbladder Cancer, Gastroesophageal (GE) Junction Carcinomas, Glioma, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, High-Grade Glioma, Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), Lung Cancer, Meningioma, Metastatic Biliary Tract Cancer, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Necrotizing Enterocolitis, Neuroblastoma, Oligodendroglioma, Ovarian Cancer, Parkinson's Disease, Pediatric Diffuse Intrinsic Pontine Glioma, Primitive Neuroectodermal Tumor (PNET), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Rhabdomyosarcoma, Skin Cancer, Systolic Heart Failure, Ulcerative Colitis, Urinary Tract Cancer and Uterine Cancer. 

Furthermore, this report also reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1)
- The report reviews Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Overview 8
Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Therapeutics Development 9
Products under Development by Stage of Development 9
Products under Development by Therapy Area 10
Products under Development by Indication 11
Products under Development by Companies 15
Products under Development by Universities/Institutes 22
Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Therapeutics Assessment 24
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Companies Involved in Therapeutics Development 30
Aslan Pharmaceuticals Pte Ltd 30
Boehringer Ingelheim GmbH 30
GamaMabs Pharma SA 32
Hanmi Pharmaceuticals Co Ltd 32
Jiangsu Kanion Pharmaceutical Co Ltd 33
Minerva Neurosciences Inc 33
Pfizer Inc 34
Puma Biotechnology Inc 35
Shanghai Fosun Pharmaceutical (Group) Co Ltd 36
XuanZhu Pharma Co Ltd 36
Zensun (Shanghai) Sci & Tech Co Ltd 37
Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Drug Profiles 38
afatinib dimaleate - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
dacomitinib - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
FCN-411 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
MIN-301 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Monoclonal Antibodies to Antagonize HER4 for Oncology - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
neratinib - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
Neucardin - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
NRG-4 - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
NT-113 - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
PB-357 - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
pirotinib - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
poziotinib - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
sirotinib - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
SKLB-1206 - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
varlitinib - Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
yinlitinib - Drug Profile 98
Product Description 98
Mechanism Of Action 98
R&D Progress 98
Z-650 - Drug Profile 99
Product Description 99
Mechanism Of Action 99
R&D Progress 99
Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Dormant Products 100
Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Discontinued Products 102
Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Product Development Milestones 103
Featured News & Press Releases 103
Jul 21, 2017: NERLYNX (neratinib) Tablets Approved for HER2+ Breast Cancer in the Extended Adjuvant Setting 103
Jul 20, 2017: NERLYNX tablets for HER2+ Breast Cancer in the Extended Adjuvant Setting 103
Jul 19, 2017: Onco360 Chosen For NERLYNX Limited Distribution Pharmacy Network 104
Jul 17, 2017: U.S. Food and Drug Administration Approves Puma's NERLYNX (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer 104
Jul 10, 2017: Lung Cancer: VeriStrat Test Identifies Patients with Squamous Cell Carcinoma of the Lung Who Are More Likely to Have Improved Survival on Afatinib Therapy 105
Jul 06, 2017: Puma Biotechnology Completes Targeted Enrollment in Neratinib Phase III Metastatic Breast Cancer Trial 105
Jun 29, 2017: Aslan Pharmaceuticals Announces First Patient Enrolled In Global Pivotal Treetopp Study For Varlitinib In Biliary Tract Cancer 106
Jun 12, 2017: Aslan Pharmaceuticals Announces MTD For Varlitinib In Combination With Chemotherapies Commonly Used In First Line Gastric Cancer 106
Jun 05, 2017: Research suggests possible new treatment for EGFR-positive lung cancer 107
Jun 03, 2017: Puma Biotechnology Announces Positive PB272 Phase II Data from TBCRC 022 Trial in Patients with HER2-Positive Metastatic Breast Cancer with Brain Metastases at the 2017 ASCO Annual Meeting 108
Jun 02, 2017: Aslan Pharmaceuticals Announces Publication of New Varlitinib Data in Metastatic Solid Tumors at ASCO 109
Jun 01, 2017: Aslan Pharmaceuticals Receives Clinical Trial Authorisation To Initiate Pivotal Study Of Varlitinib In Gastric Cancer 110
May 30, 2017: NICE Terminates Technology Appraisal for Afatinib in Advanced Squamous NSCLC After Platinum-based Chemotherapy 110
May 22, 2017: Puma Biotechnology Announces Posting of FDA Oncologic Drugs Advisory Committee Briefing Documents for Neratinib Meeting 111
May 18, 2017: New Data On Varlitinib Published At 2017 Annual Meeting Of American Society Of Cancer Oncology 111
Appendix 112
Methodology 112
Coverage 112
Secondary Research 112
Primary Research 112
Expert Panel Validation 112
Contact Us 112
Disclaimer 113

List of Tables

Number of Products under Development by Stage of Development, H2 2017 9
Number of Products under Development by Therapy Areas, H2 2017 10
Number of Products under Development by Indications, H2 2017 12
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 13
Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 14
Number of Products under Development by Companies, H2 2017 15
Products under Development by Companies, H2 2017 16
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 17
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 18
Products under Development by Companies, H2 2017 (Contd..3), H2 2017 19
Products under Development by Companies, H2 2017 (Contd..4), H2 2017 20
Products under Development by Companies, H2 2017 (Contd..5), H2 2017 21
Number of Products under Investigation by Universities/Institutes, H2 2017 22
Products under Investigation by Universities/Institutes, H2 2017 23
Number of Products by Stage and Mechanism of Actions, H2 2017 25
Number of Products by Stage and Route of Administration, H2 2017 27
Number of Products by Stage and Molecule Type, H2 2017 29
Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2017 30
Pipeline by Boehringer Ingelheim GmbH, H2 2017 31
Pipeline by GamaMabs Pharma SA, H2 2017 32
Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017 32
Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2017 33
Pipeline by Minerva Neurosciences Inc, H2 2017 33
Pipeline by Pfizer Inc, H2 2017 34
Pipeline by Puma Biotechnology Inc, H2 2017 35
Pipeline by Shanghai Fosun Pharmaceutical (Group) Co Ltd, H2 2017 36
Pipeline by XuanZhu Pharma Co Ltd, H2 2017 36
Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H2 2017 37
Dormant Products, H2 2017 100
Dormant Products, H2 2017 (Contd..1), H2 2017 101
Discontinued Products, H2 2017 102